A Phase 4 interventional study of Alflibercept in Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia. Completed at 1 site in United States. Open to participants aged 18 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-24.
Sponsored by Southeast Retina Center, Georgia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.
Among the 53 studies testing aflibercept in Macular Edema, this one is the 38th largest by enrollment, is one of 11 that started in 2015, is one of 26 in phase 4, and was the 35th registered.
759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
CMH Multan Institute of Medical Sciences · Sites in Pakistan
Ages 30–60
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 12 · Phase 4 26
First in 2006; this study’s year is marked. 11 started in 2015.
This study's enrollment of 30 is below the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 49 across the 53 interventional studies. Of the 36 that completed or were terminated, 18 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 53 have an industry lead sponsor. The 10 most frequent:
Southeast Retina Center, Georgia is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Southeast Retina Center, Georgia has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
1 of the studies testing aflibercept in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02645266McMaster UniversityMean Visual Acuity Changes Following Five Injections of Aflibercept | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 53 studies testing aflibercept in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly IAI doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
Starting at week 24, patients may be eligible to receive additional 2mg IAI (2q4) treatment if both of the following criteria is met and the investigator feels additional treatment would be beneficial:
Starting at week 24, rescue therapy with macular laser photocoagulation may be administered if any the following criteria are met
Every 4 week visit will include ETDRS BCVA, IOP measurement, Slit lamp biomicroscopy, Indirect ophthalmoscopy, Heidelberg Spectralis SD-OCT and evaluation for systemic and ocular adverse events. Fundus Photography and Wide field Optos fluorescein angiography will be performed at baseline and at week 20and week 52.
STUDY DURATION: Approximately 52 weeks to the end of the study. Primary endpoint will be evaluated at week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient must meet the following criteria to be eligible for inclusion in the study:
-
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
Sexually active men* or women of ** who are unwilling to practice adequate during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Evaluating the efficacy of Alflibercept Injections in DME Following Treatment With Bevacizumab and Ranibizumab
Drug: Alflibercept
Intravitreal Injection
Also known as: Eylea
Reduction in Macular Edema
Reduction in macular edema measured as * Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline * Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline
Time frame: 52 weeks from baseline
| Milestone | Phase 4 Prospective, Nonrandomized, Open Label, Interventional |
|---|---|
| Started | 30 |
| Completed | 27 |
| Not completed | 3 |
Reduction in macular edema measured as * Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline * Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline
| Participants | Open Label Single Arm Trial |
|---|---|
| OCT CST >350 um demonstrating >15% reduction | 15 |
| OCT CST <305um (males) | 8 |
| OCT CST<290 um (females) | 4 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 4 Prospective, Nonrandomized, Open Label, Interventional | 1/30 (3.3%) | 5/30 (16.7%) | 26/30 (86.7%) |
| Event | Phase 4 Prospective, Nonrandomized, Open Label, Interventional |
|---|---|
| Hospitalization- Low electrolytesMetabolism and nutrition disorders | 1/30 |
| DeathCardiac disorders | 1/30 |
| CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/30 |
| SepsisInfections and infestations | 1/30 |
| Kidney FailureRenal and urinary disorders | 1/30 |
| Event | Phase 4 Prospective, Nonrandomized, Open Label, Interventional |
|---|---|
| Common ColdInfections and infestations | 9/30 |
| Kidney/Liver ConditionsRenal and urinary disorders | 6/30 |
| HerniaGastrointestinal disorders | 3/30 |
| CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/30 |
| Subconjunctival HemorrhageEye disorders | 2/30 |
| Cardiovascular eventsCardiac disorders | 1/30 |
| Bladder InfectionInfections and infestations | 1/30 |
| BlepharitisInfections and infestations | 1/30 |
| Cataract ExtractionSurgical and medical procedures | 1/30 |
| Yag Laser CapsulotomySurgical and medical procedures | 1/30 |
| Age, Categorical(Participants) | Open Label Single Arm Trial |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 15 |
| >=65 years | 15 |
| Age, Continuous(years) | Open Label Single Arm Trial |
|---|---|
| Mean | 63 (43 to 85) |
| Sex: Female, Male(Participants) | Open Label Single Arm Trial |
|---|---|
| Female | 13 |
| Male | 17 |
| Race (NIH/OMB)(Participants) | Open Label Single Arm Trial |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 15 |
| White | 15 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Open Label Single Arm Trial |
|---|---|
| United States | 30 |
| Insulin Dependency (Independent/Dependent)(Participants) | Open Label Single Arm Trial |
|---|---|
| Independent | 13 |
| Dependent | 17 |
| Diabetic Retinopathy (Proliferative/Non-Proliferative)(Participants) | Open Label Single Arm Trial |
|---|---|
| Proliferative | 11 |
| Non-Proliferative | 19 |
| Average Anti-VEGF Injections Received Prior to Baseline(injections) | Open Label Single Arm Trial |
|---|---|
| Mean | 14.5 (6 to 48) |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Dec 2018, 42 months.
Results were first posted in May 2019, 5 months after primary completion.
Of 51 non-industry phase 4 interventional studies under Macular Edema, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 43. This study's 42 months is above that.
Counting every sponsor, half of 63 studies reached it within 26 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept
Southeast Retina Center, Georgia